Medical Treatment Versus Surgery in Stricturing Small Bowel Crohn's Disease

Crohn's disease (CD) is a chronic, disabling and destructive inflammatory bowel disease (IBD) leading to progressive and cumulative bowel damage, including fistulas and strictures. Strictures are defined as intestinal luminal narrowing and can lead to obstructive symptoms in the medium-to-long term. Symptomatic strictures significantly impair patient's quality of life by the presence of obstructive symptoms such as abdominal pain, nausea, vomiting, abdominal distension, and dietary restrictions leading to malnutrition. Strictures can appear anywhere in the gastrointestinal tract, but affect most commonly the terminal ileum. Epidemiological studies indicate that more than 40% of patients with ileal CD will develop strictures.

However, treatment strategies are not well-defined in this indication. Most patients undergo surgery but recent observations indicate that a medical treatment by anti-TNF may be considered in stricturing CD. The European Crohn's Colitis Organization recommends that "ileocecal CD with obstructive symptoms, but no significant evidence of active inflammation, should be treated by surgery". However, the lack of inflammation is difficult to demonstrate and does not predict the extent of fibrosis, and inflammation and fibrosis are often associated. Thus, there is a need for better defining therapeutic strategies.

The objective of the SMART trial is to compare for the first time medical versus surgical approaches in stricturing CD. Indeed, up to date, no randomized controlled trial has been conducted to compare medical treatment alone versus surgery in patients with symptomatic stricturing CD. The hypothesis is that medical treatment by a combination therapy using infliximab and azathioprine is non-inferior to surgical resection in terms of health-related quality of life (HRQoL) at 1 year, with the advantage of being conservative as regards the high rates of post-operative recurrence with the subsequent risk of small bowel syndrome, as well as highly more acceptable by patients, especially since infliximab is now available as a biosimilar in a subcutaneous formulation, which should also improve the cost-effectiveness of the medical strategy.

• IBD (inflammatory bowel disease) -related quality of life [Срок оценки: 1, 3, 6, 9, 18 and 24 months]
• Endoscopic remission [Срок оценки: 6 months]
• Obstructive symptoms [Срок оценки: 1, 3, 6, 9, 12, 18 and 24 months]
• Clinical activity [Срок оценки: 1, 3, 6, 9, 12, 18 and 24 months]
• inflammatory biomarkers (fecal calprotectin) [Срок оценки: 1, 6, 12, 18 and 24 months]
• inflammatory biomarkers ( C-reactive protein [CRP]) [Срок оценки: 1, 6, 12, 18 and 24 months]
• imaging parameters [Срок оценки: 12 months]
• treatment failures [Срок оценки: 12 and 24 months]
• patient-reported outcomes (disability) [Срок оценки: 1, 3, 6, 9, 12, 18 and 24 months]
• patient-reported outcomes (work productivity) [Срок оценки: 1, 3, 6, 9, 12, 18 and 24 months]
• patient-reported outcomes (fatigue) [Срок оценки: 1, 3, 6, 9, 12, 18 and 24 months]
• patient-reported outcomes (body image) [Срок оценки: 1, 3, 6, 9, 12, 18 and 24 months]